Novartis Norge AS, Nydalen Alle 37, Oslo, Norway.
Institute of Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, James Clerk Maxwell Building, 57 Waterloo Road, London, UK.
Eur Heart J Cardiovasc Pharmacother. 2018 Oct 1;4(4):237-242. doi: 10.1093/ehjcvp/pvy029.
The prevalence of hypertriglyceridaemia is high and growing in several parts of the world. Hypertriglyceridaemia has a well-defined association with the risk of atherosclerotic cardiovascular (CV) disease and triglycerides represent a potential target for drugs aimed at mitigating CV risk. So far, no triglyceride-lowering pharmacological strategy has succeeded in conclusively showing the ability to modify clinical outcomes. This article discusses strategic and clinical aspects of development of triglyceride-lowering drugs to address CV disease.
高甘油三酯血症在世界上的几个地区的患病率很高，且呈上升趋势。高甘油三酯血症与动脉粥样硬化性心血管（CV）疾病的风险密切相关，甘油三酯是一种潜在的药物靶点，旨在降低 CV 风险。到目前为止，还没有一种降低甘油三酯的药物治疗策略能够明确证明其具有改变临床结局的能力。本文讨论了开发降低甘油三酯药物以治疗心血管疾病的策略和临床方面。
